- Home
- CRBP vs SEER Comparison
CRBP vs SEER Comparison
Compare CRBP & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- SEER
- Stock Information
- Founded
- CRBP 2009
- SEER 2017
- Country
- CRBP United States
- SEER United States
- Employees
- CRBP N/A
- SEER N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- SEER Medicinal Chemicals and Botanical Products
- Sector
- CRBP Health Care
- SEER Health Care
- Exchange
- CRBP Nasdaq
- SEER Nasdaq
- Market Cap
- CRBP 114.8M
- SEER 113.8M
- IPO Year
- CRBP N/A
- SEER 2020
- Fundamental
- Price
- CRBP $9.50
- SEER $2.05
- Analyst Decision
- CRBP Strong Buy
- SEER
- Analyst Count
- CRBP 10
- SEER 0
- Target Price
- CRBP $53.22
- SEER N/A
- AVG Volume (30 Days)
- CRBP 91.8K
- SEER 137.3K
- Earning Date
- CRBP 11-06-2025
- SEER 11-05-2025
- Dividend Yield
- CRBP N/A
- SEER N/A
- EPS Growth
- CRBP N/A
- SEER N/A
- EPS
- CRBP N/A
- SEER N/A
- Revenue
- CRBP N/A
- SEER $16,288,000.00
- Revenue This Year
- CRBP N/A
- SEER $27.77
- Revenue Next Year
- CRBP $220.04
- SEER $20.28
- P/E Ratio
- CRBP N/A
- SEER N/A
- Revenue Growth
- CRBP N/A
- SEER 10.52
- 52 Week Low
- CRBP $4.64
- SEER $1.61
- 52 Week High
- CRBP $56.93
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- CRBP 49.85
- SEER 47.32
- Support Level
- CRBP $9.42
- SEER $1.97
- Resistance Level
- CRBP $9.73
- SEER $2.10
- Average True Range (ATR)
- CRBP 0.51
- SEER 0.05
- MACD
- CRBP -0.08
- SEER 0.00
- Stochastic Oscillator
- CRBP 15.33
- SEER 50.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.